{"blog": [], "keywords": [{"value": "Mylan Inc", "name": "organizations", "rank": "1", "is_major": "N"}, {"value": "Meda AB", "name": "organizations", "rank": "2", "is_major": "N"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "4", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/02/11/business/dealbook/mylan-in-7-2-billion-deal-for-meda-a-swedish-drug-maker.html", "document_type": "article", "byline": {"person": [{"lastname": "PICKER", "firstname": "Leslie", "role": "reported", "organization": "", "rank": 1}], "original": "By LESLIE PICKER"}, "type_of_material": "News", "multimedia": [], "section_name": "Business Day", "word_count": "436", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "Mylan is buying greater exposure to over-the-counter products, which represent 40 percent of Meda\u2019s product sales, and an entry into emerging markets.", "pub_date": "2016-02-11T00:00:00Z", "news_desk": "Business", "headline": {"main": "Mylan in $7.2 Billion Deal for Meda, a Swedish Drug Maker"}, "print_page": null, "snippet": "Mylan is buying greater exposure to over-the-counter products, which represent 40 percent of Meda\u2019s product sales, and an entry into emerging markets.", "_id": "56bbbad238f0d862fbbced39", "slideshow_credits": null, "abstract": null}